BioNxt Solutions (TSE:BNXT) has released an update.
BioNxt Solutions has expanded its patent portfolio by filing new international patents for sublingual drug delivery technologies, targeting autoimmune neurodegenerative diseases like Multiple Sclerosis and Myasthenia Gravis. The company aims to initiate clinical trials for its lead product, BNT23001, in 2025, with plans to develop strategic partnerships to accelerate commercialization.
For further insights into TSE:BNXT stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com